Johnson & Johnson’s radiopharma candidate JNJ-6420 returned mixed results in an early-stage study, demonstrating strong ...
After selling off its oral TYK2 blocker to Takeda for $4 billion, Nimbus Therapeutics has posted strong early-stage data for ...
Phase I/II data for Regeneron Pharmaceuticals’ costimulatory bispecific antibody were disappointing, with only one complete ...
Full data from the FLOW study show that Novo Nordisk’s top-selling GLP-1 receptor agonist semaglutide can significantly ...
Eli Lilly announced Friday that it is investing an additional $5.3 billion in its manufacturing site in Indiana to boost the ...
CEO Pascal Soriot on Tuesday heralded a “new era of growth” for AstraZeneca with plans to launch 20 new medicines in six ...
In advance of Friday’s Endocrinologic and Metabolic Drugs Advisory Committee meeting, the FDA has raised concerns about ...
Despite weathering a difficult year, biopharma continues to see massive pay gaps between CEOs and their median employees, ...
Riding the growing wave of interest in molecular glue degraders, Takeda has partnered with Chinese biotech Degron ...
Patent cliffs and other factors may lead other large drugmakers to embrace similar cost-cutting measures, experts tell ...
An appellate court ruled on Tuesday that pharmaceutical companies can lawfully impose restrictions on covered drugs under the ...
While Eli Lilly and Novo Nordisk currently dominate the GLP-1 receptor agonist space, there are more than 50 candidates in ...